A Prospective Controlled Study of Serum suPAR in the CsA-treated FSGS Patients
NCT ID: NCT01468493
Last Updated: 2017-04-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
90 participants
OBSERVATIONAL
2011-01-31
2019-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Efficacy and Safety of Tacrolimus in Treated Refractory Focal Segmental Glomerulosclerosis
NCT01451489
Safety Study of GC1008 in Patients With Focal Segmental Glomerulosclerosis (FSGS) of Single Doses of GC1008 in Patients With Treatment Resistant Idiopathic FSGS
NCT00464321
Pilot Studies of Novel Therapies to Treat Resistant Focal Segmental Glomerulosclerosis (FSGS)
NCT00193648
Focal Segmental Glomerulosclerosis Clinical Trial (FSGS-CT)
NCT00135811
Treating to Reduce Albuminuria and Normalize Hemodynamic Function in Focal ScLerosis With dApagliflozin Trial Effects
NCT02585804
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
steroid-sensitive FSGS
No interventions assigned to this group
steroid-dependent and resistant FSGS
No interventions assigned to this group
Healthy volunteers
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* biopsy-proven primary FSGS
* proteinuria \>=3 g/day
* without corticosteroids or CsA treatment before entry
Exclusion Criteria
* malignant tumor
* diabetes mellitus
* contraindications for the treatment of corticosteroids or CsA treatment
* untolerate to or unwilling to accept corticosteroids or CsA treatment
14 Years
70 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Guangdong Provincial People's Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Wei Shi
Director of renal division of Guangdong General Hospital
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Wei Shi, MD,PhD
Role: PRINCIPAL_INVESTIGATOR
Nephrology Dept.,Guangdong General Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Nephrology Dept.,Guangdong General Hospital
Guangzhou, Guangdong, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
GGH-1-1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.